N-acetylprocainamide Antibody (902): sc-66071

N-acetylprocainamide Antibody (902) is a mouse monoclonal IgG1 antibody that detects N-acetylprocainamide in non-species reactive samples by enzyme-linked immunosorbent assay (ELISA). N-acetylprocainamide is an active metabolite of the antiarrhythmic drug Procainamide, with enhanced potency compared to its parent compound, making N-acetylprocainamide crucial for effective cardiac arrhythmia management. N-acetylprocainamide is primarily formed in the liver and excreted through the renal system, highlighting the importance of kidney function in clearance and therapeutic efficacy. N-acetylprocainamide′s ability to block sodium channels contributes to prolonging cardiac action potential, which stabilizes heart rhythms. N-acetylprocainamide can lead to adverse effects, including autoimmune reactions, emphasizing the need for patient monitoring during treatment. N-acetylprocainamide Antibody (902) serves as an essential tool for studying pharmacokinetics and pharmacodynamics of N-acetylprocainamide, along with protein interactions in cardiac function.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

N-acetylprocainamide Antibody (902) References:

1. Antiarrhythmic potency of N-acetylprocainamide.  |  Elson, J., et al. 1975. Clin Pharmacol Ther. 17: 134-40. PMID: 1122675
2. Role of K+ channels in N-acetylprocainamide-induced relaxation of bovine tracheal smooth muscle.  |  Nakahara, T., et al. 2001. Eur J Pharmacol. 415: 73-8. PMID: 11245854
3. Pharmacokinetics of N-acetylprocainamide.  |  Atkinson, AJ. and Ruo, TI. 1986. Angiology. 37: 959-67. PMID: 2433970
4. N-acetylprocainamide's antiarrhythmic action in patients with ventricular tachycardia.  |  Somberg, J., et al. 1986. Angiology. 37: 972-81. PMID: 2433972
5. N-acetylprocainamide is a less potent inducer of T cell autoreactivity than procainamide.  |  Richardson, B., et al. 1988. Arthritis Rheum. 31: 995-9. PMID: 2457378
6. Effects of 1α,25-Dihydroxyvitamin D3 on the Pharmacokinetics of Procainamide and Its Metabolite N-Acetylprocainamide, Organic Cation Transporter Substrates, in Rats with PBPK Modeling Approach.  |  Balla, A., et al. 2021. Pharmaceutics. 13: PMID: 34452094
7. Plasma concentrations of desethyl N-acetylprocainamide in patients treated with procainamide and N-acetylprocainamide.  |  Ruo, TI., et al. 1981. Ther Drug Monit. 3: 231-7. PMID: 6172888
8. The quantitative disposition of procainamide and N-acetylprocainamide in the rat.  |  Schneck, DW., et al. 1978. J Pharmacol Exp Ther. 204: 219-25. PMID: 619132
9. Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide.  |  Roden, DM. and Woosley, RL. 1983. Pharmacol Ther. 23: 179-91. PMID: 6199801
10. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans.  |  Tisdale, JE., et al. 1995. J Clin Pharmacol. 35: 902-10. PMID: 8786250